BELLUS Health Inc  

(Public, TSE:BLU)   Watch this stock  
Find more results for BLU
+0.20 (11.17%)
May 4 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.76 - 1.99
52 week 0.76 - 1.99
Open 1.76
Vol / Avg. 202,604.00/79,342.00
Mkt cap 108.88M
P/E 467.14
Div/yield     -
EPS 0.00
Shares 54.71M
Beta 2.17
Inst. own     -
May 10, 2016
Q1 2016 BELLUS Health Inc Earnings Release (Estimated) Add to calendar
Feb 24, 2016
Q4 2015 BELLUS Health Inc Earnings Release

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 49.83% 10.06%
Operating margin 46.76% -2.63%
EBITD margin - -2.63%
Return on average assets 27.71% 2.55%
Return on average equity 40.38% 2.32%
Employees 9 -
CDP Score - -


275 Armand-Frappier Blvd
+1-450-6804500 (Phone)
+1-450-6804501 (Fax)

Website links


BELLUS Health Inc. is engaged in developing drugs for rare diseases starting with conditions that affect the kidneys. The Company's lead program is KIACTA, a drug candidate in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. KIACTA is also being developed as a treatment in a second indication called sarcoidosis, a rare inflammatory condition that affects the lungs. In addition, the Company is developing Shigamab, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Its pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.